Research programme: diabetic nephropathy therapeutics - Boehringer Ingelheim/University of Michigan

Drug Profile

Research programme: diabetic nephropathy therapeutics - Boehringer Ingelheim/University of Michigan

Latest Information Update: 02 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim; University of Michigan
  • Developer Boehringer Ingelheim; National Institutes of Health (USA); University of Michigan; University of Minnesota
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetic nephropathies

Most Recent Events

  • 28 May 2015 Boehringer Ingelheim and the University of Michigan agree to co-develop diabetic nephropathy therapeutics
  • 28 May 2015 Early research in Diabetic nephropathies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top